Stoll Katie, Lutgendorf Monica, Knutzen Dana, Nielsen Peter E
Madigan Army Medical Center, Department of Obstetrics and Gynecology, Tacoma , WA , USA.
J Matern Fetal Neonatal Med. 2014 Apr;27(6):633-4. doi: 10.3109/14767058.2013.820699. Epub 2013 Jul 31.
Prenatal testing for Down syndrome through the use of non-invasive prenatal testing (NIPT) has been increasingly implemented in clinical practice and a recent cost analysis suggests that NIPT is cost effective when compared to other screening modalities in high risk populations. However, this anaylsis makes many assumptions regarding uptake of testing and pregnancy termination, which cannot be applied to all populations in the United States. Additionally, this cost analysis, which hinges on fewer Down syndrome births, does not align with the goals of prenatal testing to support autonomous and value consistent decisions. NIPT is an expensive new technology and more careful analysis is needed to determine the impact of NIPT on outcomes and overall healthcare costs.
通过使用无创产前检测（NIPT）进行唐氏综合征的产前检测已在临床实践中越来越多地得到应用，最近的一项成本分析表明，与高风险人群中的其他筛查方式相比，NIPT具有成本效益。然而，该分析对检测的接受情况和妊娠终止做出了许多假设，这些假设不适用于美国的所有人群。此外，这项依赖于唐氏综合征出生数量减少的成本分析与产前检测支持自主且符合价值观的决策的目标不一致。NIPT是一项昂贵的新技术，需要更仔细的分析来确定NIPT对结果和总体医疗成本的影响。
